Business Context and Reporting Period
This Form 8-K Current Report was filed by ImmuCell Corporation on September 29, 2025. The filing discloses the entry into a material definitive agreement regarding the appointment of a new Chief Executive Officer and the departure of the current CEO.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and corporate governance changes.
Material Changes
- Executive Leadership Transition: Olivier te Boekhorst has been elected to serve as President and Chief Executive Officer, effective November 1, 2025.
- Departure of Current CEO: Michael F. Brigham will step down as President and CEO upon Mr. te Boekhorst's commencement. Mr. Brigham will transition to the role of Special Advisor to the CEO for at least two months to ensure a smooth transition and will remain a Director.
- Board Expansion: The Board of Directors will expand to include Mr. te Boekhorst as a Director following his employment commencement.
Compensation, Outlook, and Risks
Compensatory Arrangements for Olivier te Boekhorst
- Base Salary: $450,000 annually.
- Signing Bonus: One-time payment of $100,000 (subject to repayment if employment ceases within one year).
- Annual Bonus: Eligible for up to $400,000 annually, contingent on achieving financial improvement targets set by the Board. Targets for 2026 are to be negotiated in Q1 2026.
- Equity Grants:
- First Installment: Nonqualified stock option for 76,673 shares at an exercise price of $5.90 per share, granted September 16, 2025.
- Second Installment: Up to 85,000 shares (mix of incentive and nonqualified options) to be granted shortly after the start date, with a projected accounting value of $250,000.
- Vesting: Three equal annual increments starting on the first anniversary of the grant date. Full acceleration occurs upon a Change in Control.
- Severance: In the event of termination without Cause or resignation for Good Reason, Mr. te Boekhorst is eligible for one year's base salary, up to 12 months of COBRA reimbursement, up to 12 months of accelerated vesting, and a 24-month exercise period for vested options.
Management Commentary and Risks
The filing indicates a strategic shift in leadership to drive financial improvement, as evidenced by the bonus structure tied to specific financial targets. The filing incorporates by reference a Confidential Information, Inventions, and Noncompete Agreement, which poses standard risks regarding the retention of proprietary information and non-competition obligations.
Investor Verification Checklist
- Verify the exact vesting schedule and performance metrics for the $400,000 annual bonus in the attached Employment Agreement (Exhibit 10.1).
- Confirm the final share count and exercise price for the second installment of stock options once granted.
- Review the definition of "Change in Control" within the agreement to understand acceleration triggers.
- Monitor the transition period to ensure Mr. Brigham's role as Special Advisor does not create governance conflicts.
- Check subsequent filings for the negotiation of 2026 financial improvement targets.